Abstract 120: Surpass Flow Diverter for Endovascular Treatment of Intracranial Aneurysms - A Multicenter Preliminary Clinical and Angiographic Experience in 161 Patients with 186 Aneurysms
Objective: Validated through experimental studies a new generation of flow diverters (Surpass™ FD) was evaluated for treatment of intracranial aneurysms (IA). We present our multicenter preliminary clinical and angiographic experience.
METHODS: To achieve the calculated flow disruption between the parent artery and aneurysm for thrombosis, single FDs were placed endovascularly in parent arteries. Implants measured 2.5-5.3mm in diameter with a length of 10-80mm. Patients were enrolled harboring a wide range large and giant wide-neck, fusiform and multiple small and blister-type aneurysm. Clinical and angiographic follow-up were performed at 1-3, 6, and 12 months.
RESULTS: A total of 186 consecutive IA in 161 patients (mean age 57.1 years) were treated at 33 centers. Fifty-three aneurysms were smaller than 5 mm, 64 were 5-9.9mm in diameter, 47 were 10-20mm in diameter, and 22 were larger than 20mm (10.4±0.7mm, neck size 6.0±0.5mm [mean±SEM]) . The aneurysms originated in 63.4% from the internal carotid artery; 22% and 14.5% of the lesions were located in the anterior circulation distal to Circle of Willis and posterior circulation respectively. Technical success was achieved in 182 aneurysms (98%); average number of devices used per aneurysm was 1.05. Permanent morbidity and mortality during the follow-up period of mean 8.4months (range 1-24 months) including periprocedural complications for patients with aneurysms of the anterior circulation were encountered in 5 (3.7%) and 2 (1.5 %) patients respectively and 1 (3.7%) and 4 (14.8%) respectively for patients with aneurysms of the posterior circulation location. One-hundred-ten patients (70.5%) harboring 127 (70.2%) were available for clinical and angiographic follow-up and showed a complete or near complete aneurysm occlusion in 63 (81.8%) of the ICA. Aneurysms of the ICA≥10mm that were completely covered by FD and not previously stent-treated with a minimum of 6 months follow-up available in 16 patients showed a complete obliteration in 81.3% (n=13) and >90% occlusion in remaining 3 patients.
CONCLUSION: Preliminary data demonstrate high safety and efficacy of a new generation of FD for a wide range of IA of the anterior and posterior circulation with a single implant.
Author Disclosures: A.K. Wakhloo: Research Grant; Significant; Philips Medical. Speakers' Bureau; Modest; Miami Baptist Health Care, Harvard Postgraduate Course. Consultant/Advisory Board; Significant; Stryker Neurovascular, Boston Biomedical Associates. P. Lylyk: None. J. de Vries: Consultant/Advisory Board; Significant; Stryker Neurovascular. M.J. Gounis: Research Grant; Significant; NIH, Stryker, Philips Med, Concentric Medical, Neurointerventional Therapeutics, Sanofi-aventis, Thrombolytic Scine Inc.. Other Research Support; Significant; eV3,. Consultant/Advisory Board; Modest; Codman Neurovascular. Consultant/Advisory Board; Significant; Stryker Neurovascular. A. Biondi: None. C. Taschner: Consultant/Advisory Board; Significant; Stryker Neurovascular. M. Hartmann: None. I. Szikora: Research Grant; Modest; Grant: Covidien/ev3,* National Science and Research Fund (OTKA), Hungary. Consultant/Advisory Board; Modest; Covidien/eV3, Stryker Neurovascular. L. Pierot: Consultant/Advisory Board; Modest; Sequent, Codman Neurovascular, eV3, Penumbra. N. Sakai: None. E. Boccardi: Consultant/Advisory Board; Significant; eV3. F. Turjman: None. N. Sourour: Consultant/Advisory Board; Significant; eV3.
- © 2014 by American Heart Association, Inc.